LTβR nonclassical NFκB blocking peptide

The LTβR nonclassical NFκB blocking peptide (nciLT) is a cell-permeable decoy peptide designed to selectively inhibit the nonclassical (alternative) NFκB signaling pathway mediated by the lymphotoxin-beta receptor (LTβR). Developed in the laboratory of Jonathan Bromberg at the University of Maryland, the peptide consists of a fragment of the LTβR intracellular TRAF recruitment domain fused to a cell-penetrating sequence from the Drosophila antennapedia peptide. Its mechanism involves sequestering TRAF3 from the LTβR signaling complex, which prevents NIK-mediated processing of p100 to p52 and reduces the production of homeostatic chemokines such as CCL21 and CXCL12. Preclinical studies have demonstrated its potential in treating inflammatory conditions, promoting transplant tolerance, and inhibiting melanoma metastasis by suppressing tumor cell migration and growth.

Other names

LTβR-nonclassical NFκB blocking peptideLTβR nonclassical NFκB inhibitor peptide